

Clinical Policy: Quinine Sulfate (Qualaquin)

Reference Number: CP.PMN.262

Effective Date: 06.01.21

Last Review Date: 05.25

Line of Business: Commercial, HIM, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Quinine sulfate (Qualaquin[®]) is an antimalarial drug.

FDA Approved Indication(s)

Qualaquin is indicated for treatment of uncomplicated *Plasmodium falciparum* malaria.

Quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented.

Limitation(s) of use: Qualaquin is not approved for:

- Treatment of severe or complicated *P. falciparum* malaria
- Prevention of malaria
- Treatment or prevention of nocturnal leg cramps

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that quinine and Qualaquin are **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Malaria (must meet all):

1. Diagnosis of one of the following (a or b):
 - a. Uncomplicated *Plasmodium falciparum* malaria;
 - b. Uncomplicated *Plasmodium vivax*, *Plasmodium ovale*, *Plasmodium malariae*, or *Plasmodium knowlesi* malaria (off-label);
 2. Failure of a formulary antimalarial agent (e.g., atovaquone-proguanil, Coartem[®], chloroquine, hydroxychloroquine, mefloquine), unless clinically significant adverse effects are experienced, all are contraindicated, or the causative species is resistant to all formulary antimalarial agents;*
- *For Illinois HIM requests, the step therapy requirements above do not apply to generic quinine as of 1/1/2026 per IL HB 5395*
3. If request is for brand Qualaquin, member must use generic quinine, unless contraindicated or clinically significant adverse effects are experienced;
 4. Dose does not exceed 1,944 mg (6 capsules) per day.

Approval duration: 7 days

B. Babesiosis (off-label) (must meet all):

1. Diagnosis of babesiosis;
2. Prescribed in combination with clindamycin;
3. If request is for brand Qualaquin, member must use generic quinine, unless contraindicated or clinically significant adverse effects are experienced;
4. Dose does not exceed 1,944 mg (6 capsules) per day.

Approval duration: Duration of request or 10 days (whichever is less)

C. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. Malaria or Babesiosis (off-label)

1. Re-authorization is not permitted. Member must meet the initial approval criteria.

Approval duration: Not applicable

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line

of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace, and CP.PMN.53 for Medicaid, or evidence of coverage documents;
- B. Prevention of malaria;
- C. Treatment or prevention of nocturnal leg cramps.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

CDC: Centers for Disease Control and Prevention

FDA: Food and Drug Administration

G6PD: glucose-6-phosphate dehydrogenase
HUS/TTP: hemolytic uremic syndrome/
thrombotic thrombocytopenic purpura

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
atovaquone-proguanil (Malarone [®])	Adults: 1 gram atovaquone/400 mg proguanil hydrochloride PO QD for 3 days	See dosing regimen
Coartem [®] (artemether/lumefantrine)	Adults: 80 mg artemether/480 mg lumefantrine PO initially, then a second dose 8 hours later, then 1 dose PO twice daily (morning and evening) for the next 2 days for a total course of 24 tablets	8 tablets/day (total of 6 doses over 3 days)
chloroquine (Aralen [®])	Adults: 1,000 mg (600 mg base) PO, then 500 mg (300 mg base) PO in 6 to 8 hours, then 500 mg (300 mg base) PO QD for 2 days.	1 g (600 mg base) PO as initial dose(s) for malaria treatment; otherwise, 500 mg/dose (300 mg base/dose) PO.
hydroxychloroquine (Plaquenil [®])	Adults: 800 mg (620 mg base) PO, then 400 mg (310 mg base) PO at 6, 24, and 48 hours after the initial dose for a total dose of 2 g (1.55 g base)	See dosing regimen
mefloquine	Adults: 1,250 mg (administered as five 250 mg tablets) PO as a single dose. Alternatively, 750 mg PO as the	See dosing regimen

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
	initial dose, then 500 mg PO 6 to 12 hours later	

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s):
 - Prolongation of QT interval
 - Glucose-6-phosphate dehydrogenase (G6PD) deficiency
 - Myasthenia gravis
 - Known hypersensitivity to quinine, mefloquine, or quinidine
 - Optic neuritis
- Boxed warning(s): Quaaliquin use for the treatment or prevention of nocturnal leg cramps may result in serious and life-threatening hematologic reactions, including thrombocytopenia and hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP). Chronic renal impairment associated with the development of TTP has been reported. The risk associated with Quaaliquin use in the absence of evidence of its effectiveness in the treatment or prevention of nocturnal leg cramps outweighs any potential benefit.

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Malaria	Adults (≥ 16 years of age): 648 mg (two capsules) PO Q8h for 3-7 days Guidelines recommend use in chloroquine-resistant infections and for infections of unknown resistance, though quinine may also be used in chloroquine-sensitive infections if necessary. Use in combination with doxycycline, tetracycline, or clindamycin. For <i>P. vivax</i> or <i>P. ovale</i> infections, add primaquine phosphate.	1,944 mg/day
Babesiosis (off-label)	Adults: 648 mg PO TID with concurrent administration of clindamycin PO or IV for 7-10 days	1,944 mg/day

VI. Product Availability

Capsule: 324 mg

VII. References

1. Quaaliquin Prescribing Information. Philadelphia, PA: Mutual Pharmaceutical Company, Inc. June 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021799s029lbl.pdf. Accessed January 24, 2025.

2. Micromedex[®] Healthcare Series [Internet database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Accessed February 3, 2025.
3. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2025. Available at: <http://www.clinicalpharmacology-ip.com/>. Accessed February 3, 2025.
4. Centers for Disease Control and Prevention. Malaria in the United States: Treatment tables. Available at: https://www.cdc.gov/malaria/media/pdfs/2024/08/Malaria_Treatment_Table_20240814.pdf. Last updated August 14, 2024. Accessed February 3, 2025.
5. Centers for Disease Control and Prevention. Clinical care of babesiosis. <https://www.cdc.gov/babesiosis/hcp/clinical-care>. Last updated February 13, 2024. Accessed February 3, 2025.
6. Krause PJ, Auwaerter PG, Bannuru RR, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA): 2020 guideline on diagnosis and management of babesiosis. *Clinical Infectious Diseases*. 2021; 72(2): e49-e64.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created (adapted from CP.PCH.10; policy to retire); added Medicaid line of business; added that request is for generic formulation; references reviewed and updated.	02.15.21	05.21
2Q 2022 annual review: for babesiosis, added requirement for use in combination with clindamycin per IDSA and CDC; references reviewed and updated.	01.25.22	05.22
Template changes applied to other diagnoses/indications.	10.06.22	
2Q 2023 annual review: no significant changes; references reviewed and updated.	01.23.23	05.23
2Q 2024 annual review: revised policy/criteria section to also include generic quinine; for malaria, added <i>Plasmodium ovale</i> , <i>Plasmodium malariae</i> , and <i>Plasmodium knowlesi</i> as additional off-label coverable infections per CDC guidelines; for babesiosis, added redirection to generic; updated malaria dosing recommendations in Section V per Clinical Pharmacology; references reviewed and updated	02.07.24	05.24
2Q 2025 annual review: no significant changes; removed Appendix D with supplemental links on malaria and babesiosis; references reviewed and updated. Added step therapy bypass for IL HIM per IL HB 5395.	04.07.25	05.25

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and

accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2018 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.